This is an exceptionally good result for a diagnostic test
Pancreatic cancer is often detected at a late stage, which results in poor prognosis and limited treatment options. Researchers at The Sahlgrenska Academy have now developed a method which identifies the cancer’s visible precursors with 97% certainty. The method, which is expected to aid in the early discovery of the cancer as well as minimize the risk of unnecessary surgery, may be introduced in patient care within five years.
The poor prognosis for pancreatic cancer, where only 5 percent of the patients survive five years after the diagnosis, is due to the fact that the tumors often develop unnoticed, and rarely cause symptoms until they have spread to other organs.
Recent studies, however, have shown that fluid-filled compartments in the pancreas, called cysts, may be precursors of the cancer.
Hard to identify harmful cysts
Cysts in the pancreas, which are found in every 10th person above the age of 70, and are also common in younger people, can be discovered with computed tomography (CT) or magnetic resonance imaging (MRI).
The problem is that imaging alone cannot determine which cysts are at risk for developing into cancer. Therefore, it often becomes necessary to puncture the cyst and look for tumor markers in the cyst fluid but not even these analyses are reliable.
Removing the cyst by surgery, with the knowledge that it may turn out to be completely benign, is also problematic since the operation is extensive, with considerable risks for the patient.
97 percent certainty
Researchers at The Sahlgrenska Academy, University of Gothenburg, have now developed a method which can predict with 97 percent certainty which pancreatic cysts constitute precursors to cancer. With this method, which detects the presence of mucus protein, mucins, in the cystic fluid, the researchers were able to reach the correct diagnosis in 77 of 79 cysts that were examined.
– This is an exceptionally good result for a diagnostic test, and we are very hopeful that the method will enable more instances of early discovery of pancreatic cancer, at a stage when the cancer can be treated or prevented. This approach may also minimize the risk of unnecessary operations on non-malignant cysts, said Karolina Jabbar, PhD student at The Sahlgrenska Academy and physician at The Sahlgrenska University Hospital.
Helps operation decisions
The researchers have also tested the new method in order to analyze existing tumors and, with about 90 percent certainty, have been able to determine which tumors have already developed into cancers. This means that the method could also be used to determine which patients require immediate surgery, and when it is instead possible to wait and monitor the development of the cyst.
The method which has been used in the study is called proteomics, which means the analysis of the protein content of a tissue or fluid with the help of mass spectrometry . This method has thus far been used in research. But Professor Gunnar C. Hansson who, together with senior physician and Assistant Professor Riadh Sadik, initiated the study, is convinced that the proteomics will soon be introduced in health care.
– The technique has been developed, and we can now measure biomarkers both quickly and exactly. Moreover, the method requires minimal biomaterial, in this case 25 times less cyst fluid than conventional tumor marker analyses. I am certain that within five years the mass spectrometers will have moved into the hospital corridors, he said.
The Latest on: Pancreatic Cancer
via Google News
The Latest on: Pancreatic Cancer
- Pleasanton Police Officer Loses Battle With Pancreatic Canceron October 18, 2019 at 2:09 pm
PLEASANTON (CBS SF) — A Pleasanton police officer who was battling pancreatic cancer for the past year died earlier this week. 36-year-old officer Kyle Henricksen had been with the Pleasanton Police ...
- What you need to know about Pancreatic Canceron October 18, 2019 at 10:07 am
Pancreatic cancer is the third leading cause of cancer death in the United States. And it can be difficult to catch early and it's often found incidentally, at a routine appointment or because of some ...
- ‘The 10 Percent Club’: Researchers Try To Determine Why Some Pancreatic Cancer Patients Outlive The Oddson October 17, 2019 at 3:34 pm
PITTSBURGH (KDKA) – Six years ago, Kathy Miller had severe pain in her back. She thought it was her gallbladder. She was stunned when the doctors told her it was pancreatic cancer. “It just kind of ...
- Lilly's Pancreatic Cancer Candidate Fails in Phase III Studyon October 17, 2019 at 9:12 am
Eli Lilly and Company LLY announced that its immunotherapy candidate, pegilodecakin, in combination with chemotherapies, failed to show survival benefit in a phase III SEQUOIA study, evaluating the ...
- SPOP suppresses pancreatic cancer progression by promoting the degradation of NANOGon October 17, 2019 at 8:26 am
It appears to help regulate progression of several cancers, and we show here that it acts as a tumor suppressor in pancreatic cancer. Our analysis of patient tissues showed decreased SPOP expression, ...
- Eli Lilly Phase 3 Pancreatic Cancer Study Fails to Meet Primary Endpointon October 16, 2019 at 5:21 am
The late-stage trial of patients with metastatic pancreatic cancer 'did not meet its primary endpoint of overall survival,' Eli Lilly says. Lilly shares fell 1.6% to $108 in premarket trading. The ...
- Lilly's pancreatic cancer treatment fails late-stage studyon October 16, 2019 at 4:21 am
(Reuters) - Eli Lilly and Co said on Wednesday its experimental pancreatic cancer treatment in combination with a cocktail of chemotherapies did not meet the main goal in a late-stage study. The trial ...
- Lilly Announces Phase 3 Study in Patients with Metastatic Pancreatic Cancer Did Not Meet Primary Endpoint of Overall Survivalon October 16, 2019 at 4:09 am
Lilly Announces Phase 3 Study in Patients with Metastatic Pancreatic Cancer Did Not Meet Primary Endpoint of Overall Survival PR Newswire INDIANAPOLIS, Oct. 16, 2019 INDIANAPOLIS, Oct. 16, 2019 ...
- NanOlogy to Present Interim Data for Pancreatic Cancer and Mucinous Cystic Neoplasms of the Pancreas with Local Injection of NanoPac®on October 15, 2019 at 5:08 pm
The pancreatic cancer abstract presents interim clinical data on intratumoral delivery of NanoPac for treatment of locally advanced pancreatic cancer on October 29 th at 8:40AM by Simon K. Lo, MD ...
- Global Pancreatic Cancer Therapeutics Diagnostics Market Growth, Trends and Forecast 2016-2022on October 15, 2019 at 5:02 am
The uncontrolled growth of cells in the pancreas causes pancreatic cancer. It is an abnormal, unrestrained growth of cells which leads to formation of lumps in the tissues, usually referred to as ...
via Bing News